Shandong Sinobioway Biomedicine (002581.SZ) announced its 2024 half-year performance forecast, with a net loss of 23 million yuan to 42 million yuan attributable to shareholders of the listed company, compared with a loss of 53.7573 million yuan in the same period last year; net profit after deducting non-recurring gains and losses was a loss of 20.4 million yuan to 39.4 million yuan, compared with a loss of 48.1417 million yuan in the same period last year; basic earnings per share were a loss of 0.0349 yuan/share to 0.0637 yuan/share.
During the reporting period, the reason for the company's losses was a decrease in investment income. The company will further carry out a new round of global strategy planning, follow the market trend, actively explore the extension of product applications to respond to market changes. During the reporting period, the net income attributable to shareholders of the listed company increased compared to the same period last year, mainly due to the company's continuous improvement of internal efficiency through cost reduction and lean production and other methods.
